Hilde Hermansen Steineger

Biography

  Dr. Hilde Hermansen Steineger, Ph.D., served as Head of Global Omega-3 Innovation Management at Pronova BioPharma. Dr. Steineger serves as Vice President of Business Development at Pronova BioPharma ASA and Pronova BioPharma Norge AS. She serves as the Chief Operating Officer of Padtech AS. She works at business development in AminoAS. She served as Vice President of Investor Relations & Communications at Pronova BioPharma ASA until December 1, 2009. She served as the Head of Investor Relations at Pronova Biopharma Norge AS since 2007 and Pronova BioPharma ASA from 2007 to 2010. She served as Head of Corporate Communications at Pronova BioPharma Norge AS. From 2001 to 2004, she served as an Equity Analyst in Kreditkassen (now part of Nordea) and Nordea Markets, Research Division. Dr. Steineger served as the Senior Associate at NeoMed from 2006 to 2007 and also served as Business Development Consultant of Maxfield/Amino from 2003 to 2006. She served as a Senior Financial Analyst of Nordea Securities from 2001 to 2003. From 2004 to 2006, Dr. Steineger served as an Independent Advisor focusing on start-ups within the Life Science/Health Care sector. She held clinical research and international marketing positions at Nycomed Pharma from 1999 to 2001. She has been a Director of Nordic Nanovector ASA since November 2014, Algeta ASA since December 2007, PCI Biotech Holding ASA since May 2014, PCI Biotech AS since May 2014 and Biotec Pharmacon since 2007. She serves as a Director at Strongbridge Biopharma plc (also known as Cortendo AB) and Invent 2 AS since Janauary 2014. She served as a Director at Clavis Pharma AS from 2007 to June 2013 and Weifa AS from 2007 to June 2013. She served as a Director of Aqualis ASA. Dr. Steineger holds a Ph.D in Medical Biochemistry in 2000 and an M.Sc. in Biotechnology from the University of Oslo. She also holds B.S from the University of Oslo.

Research Interest

biotechnology